<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anemia is common among patients with chronic kidney disease (CKD). Anemia underlies many of the symptoms associated with reduced kidney function and is associated with increased mortality and hospitalizations [<a href="#rid1">1-4</a>].</p><p>Among patients with CKD, iron deficiency is a common, reversible cause of anemia and resistance to erythropoiesis-stimulating agents (ESAs). The administration of iron is necessary for treatment of iron deficiency and, in selected patients, may allow a higher hemoglobin (Hb) in the absence of ESAs.</p><p>This topic reviews screening for iron deficiency, the indications for iron therapy, and options for treatment of iron deficiency among patients with nondialysis CKD. The treatment of iron deficiency in patients on dialysis is discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1953.html" rel="external">"Treatment of iron deficiency in patients on dialysis"</a>.)</p><p></p><p>Indications for treatment with ESAs are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H205762983"><span class="h1">DIAGNOSIS OF IRON DEFICIENCY</span><span class="headingEndMark"> — </span>We use the serum iron, total iron-binding capacity (TIBC), serum ferritin, and calculation of the percent transferrin saturation (TSAT) to estimate iron stores. Other methods including the percentage of hypochromic red blood cells (RBCs) or reticulocyte hemoglobin (Hb) content are not widely available in the United States but may be more widely used in Europe [<a href="#rid5">5</a>]. Bone marrow biopsies are considered the gold standard for diagnosis but are not commonly used among patients with CKD.</p><p>The laboratory criteria for TSAT and serum ferritin that are used to diagnose iron deficiency in patients with CKD are markedly different from those in patients with relatively normal kidney function. Laboratory criteria for the diagnosis of absolute and functional iron deficiency in patients with nondialysis CKD and in patients on dialysis are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1951.html" rel="external">"Diagnosis of iron deficiency in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H3835935612"><span class="h1">SCREENING FOR ANEMIA AND IRON DEFICIENCY</span></p><p class="headingAnchor" id="H2307889976"><span class="h2">Initial screen</span><span class="headingEndMark"> — </span>All patients with CKD, particularly those with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m<sup>2</sup>, should be screened for anemia on initial evaluation for CKD. We screen for anemia using measurement of hemoglobin (Hb) concentration. </p><p>Patients who are found to be anemic should be evaluated for cause. The initial evaluation of anemia is generally the same for patients with CKD as in the general population. The evaluation should include complete blood count, red blood cell (RBC) indices, reticulocyte count, serum iron, total iron-binding capacity (TIBC), percent transferrin saturation (TSAT), serum ferritin, serum folate and vitamin B12 levels, and testing for occult blood in stool. (See  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p>In a recent study of over 5 million individuals, low iron indices (defined as TSAT ≤20 percent and/or ferritin ≤100 ng/mL) were noted in approximately half of males and over half of females who had anemia and eGFR &lt; 60 mL/min/1.73 m<sup>2</sup> [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H2430225913"><span class="h2">Continued monitoring</span><span class="headingEndMark"> — </span>After the initial screen and evaluation, we continue to routinely monitor all patients with CKD for anemia and iron deficiency. Screening tests for iron deficiency include the percent TSAT, which is the serum iron divided by TIBC x 100, and the serum ferritin concentration. (See  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p>The optimal frequency of repeat testing is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Continued monitoring'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">INDICATIONS FOR TREATMENT</span><span class="headingEndMark"> — </span>The indications for iron administration are based upon the transferrin saturation (TSAT), ferritin, and, in some patients, the hemoglobin (Hb). </p><p class="bulletIndent1"><span class="glyph">●</span>We give iron to most anemic patients with CKD who have a TSAT ≤20 percent and/or a serum ferritin concentration ≤100 ng/mL. Such patients are likely to have decreased iron stores (ie, absolute iron deficiency) and will have an increase in Hb concentration with iron supplementation. (See  <a class="medical medical_review" href="/z/d/html/1951.html" rel="external">"Diagnosis of iron deficiency in chronic kidney disease", section on 'Definitions'</a>.)</p><p></p><p>While anemia is commonly defined as an Hb concentration &lt;13.0 g/dL for adult males and postmenopausal women and an Hb &lt;12.0 g/dL for premenopausal women, we would not treat all such patients, but rather only those for whom an increase in Hb concentration is desired [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Definition'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>We give iron to some anemic patients with CKD who have a TSAT between 20 and 30 percent and ferritin between 100 and 500 ng/mL. Although such patients are likely to have adequate iron stores, they may have insufficient iron availability for erythropoiesis (ie, functional iron deficiency) and many will respond to iron with an increase in Hb concentration or decrease in erythropoiesis-stimulating agent (ESA) dose [<a href="#rid8">8-14</a>]. Thus, we give iron if an increase in Hb and/or avoidance of ESAs is desired. (See  <a class="medical medical_review" href="/z/d/html/1951.html" rel="external">"Diagnosis of iron deficiency in chronic kidney disease", section on 'Definitions'</a> and  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Definition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not give iron to patients with CKD who have a TSAT &gt;30 percent, since such patients are unlikely to respond to iron. We do not routinely administer iron to patients with ferritin levels &gt;500 ng/mL, although each patient should be individually assessed. As an example, some patients at high risk for iron deficiency (such as those with chronic gastrointestinal bleeding) will have a TSAT ≤20 percent and may have a ferritin &gt;500 ng/mL and may benefit from iron. Among such patients, trends in ferritin concentration and TSAT in response to iron should be followed.</p><p></p><p>Among patients with CKD, absolute iron deficiency was associated with a higher risk of hospitalization for cardiovascular disease, but not with mortality or need for dialysis [<a href="#rid15">15</a>]. Whether treatment of iron deficiency modifies this risk is not known. </p><p class="headingAnchor" id="H8"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3175756367"><span class="h2">Route of administration</span><span class="headingEndMark"> — </span>Iron may be given orally or intravenously [<a href="#rid5">5</a>]. The route of administration is selected based upon the severity of anemia and iron deficiency, the patient's ability to tolerate oral iron, the response to prior oral iron therapy, history of adverse reactions to intravenous iron, and the availability of venous access.</p><p>We give oral iron to most patients with nondialysis CKD who are selected for iron therapy. Oral iron is inexpensive, readily available, and does not require intravenous access.</p><p>We give intravenous iron to selected patients who require more rapid repletion of iron, who cannot tolerate oral iron, who have not responded to it, or who are unlikely to be effectively treated with oral iron, including most patients with symptomatic anemia, provided that blood transfusion can be safely deferred. As examples, we give intravenous iron to patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe iron deficiency (ie, transferrin saturation [TSAT] &lt;12 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe anemia (hemoglobin [Hb] &lt;7 g/dL) in asymptomatic patients</p><p class="bulletIndent1"><span class="glyph">●</span>Risk of ongoing blood loss (such as a patient with chronic gastrointestinal blood loss)</p><p class="bulletIndent1"><span class="glyph">●</span>History of side effects to oral iron that limit adherence</p><p class="bulletIndent1"><span class="glyph">●</span>History of not responding adequately to oral iron</p><p></p><p>Randomized studies have reported inconsistent findings concerning the relative efficacy of oral iron and intravenous iron therapy among patients with nondialysis CKD [<a href="#rid14">14,16-20</a>]. In a meta-analysis including over 3000 adults and children with all stages of CKD, intravenous iron was superior to oral iron for achieving target Hb, increasing Hb and iron test parameters, and avoiding ESAs [<a href="#rid21">21</a>]. Compared with patients who received oral iron, more patients who received intravenous iron experienced allergic reactions and hypotension, but fewer had gastrointestinal adverse effects. There was insufficient evidence to determine whether the route of administration (oral or intravenous) affected mortality, infection risk, or quality of life.</p><p>We and others believe that the benefit outweighs the risk of intravenous iron in most patients with CKD who meet the criteria listed above [<a href="#rid22">22,23</a>].</p><p>The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have recommended that either oral iron therapy or intravenous iron therapy can be given in patients not on dialysis [<a href="#rid24">24</a>]. The National Institute for Health and Care Excellence (NICE) guidelines suggest using oral iron for individuals who are not on ESAs and offering intravenous iron to those who do not tolerate oral therapy or do not reach targets within three months [<a href="#rid25">25</a>]. The NICE guidelines suggest intravenous iron for those who are being treated with ESAs [<a href="#rid25">25</a>]. The European Best Practice Guidelines suggest that intravenous iron is the optimal route of administration, but, for practical reasons, oral iron may be considered among patients with CKD who are not on dialysis [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H1652554978"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The goal of iron therapy is to correct absolute iron deficiency and/or to increase Hb level to that desired for the particular patient. We generally provide sufficient iron to accomplish this while attempting to maintain the TSAT ≤30 percent and the ferritin level ≤500 mg/mL. Although the dose varies among individual agents, a course of intravenous iron usually provides 1000 mg elemental iron. (See <a class="local">'Intravenous iron'</a> below.)</p><p>Some patients will not increase Hb to desired values despite achieving a TSAT of approximately 30 percent. Such patients may be candidates for treatment with ESAs. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Erythropoiesis-stimulating agents'</a>.)</p><p>There are no randomized, controlled trials that have compared different iron target levels among nondialysis patients. Support for the specific iron target levels are derived almost entirely from data among in-center hemodialysis patients. However, evidence from in-center hemodialysis patients may not directly apply to nondialysis and peritoneal dialysis patients, since dialysis-related blood loss does not occur. The studies that have examined these issues are discussed in detail separately. </p><p>Iron indices should be re-evaluated after therapy, typically one month following a dose of intravenous iron or the last dose of a planned series of infusions, and every three months among patients receiving oral iron. For patients treated with oral iron, we usually switch to intravenous treatment if iron status tests and Hb are not improving and remain below goal.</p><p>Iron indices generally respond to intravenous iron therapy. Patients who do not achieve target TSAT and ferritin values, or at least show significant improvement in iron stores, despite intravenous iron should be evaluated for sources of blood loss, particularly gastrointestinal bleeding.</p><p class="headingAnchor" id="H10"><span class="h2">Individual agents</span></p><p class="headingAnchor" id="H2479031825"><span class="h3">Oral iron</span><span class="headingEndMark"> — </span>Oral iron can be given among patients with nondialysis CKD using either one of the following dosing regimens:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Daily dosing</strong> – Daily administration with goal elemental iron intake of approximately 200 mg per day in up to three divided doses. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternate-day dosing</strong> – Alternate-day administration with goal elemental iron intake of approximately 65 mg per day in a single dose.</p><p></p><p>We typically use <a class="drug drug_general" data-topicid="8444" href="/z/d/drug information/8444.html" rel="external">ferrous sulfate</a> 325 mg (65 mg elemental iron) to achieve this goal elemental iron dose. Other alternative iron preparations include <a class="drug drug_general" data-topicid="8442" href="/z/d/drug information/8442.html" rel="external">ferrous fumarate</a> and <a class="drug drug_general" data-topicid="8443" href="/z/d/drug information/8443.html" rel="external">ferrous gluconate</a>; these are available in various doses with variable elemental iron content  (<a class="graphic graphic_table graphicRef106069" href="/z/d/graphic/106069.html" rel="external">table 1</a>). </p><p>Oral iron should be administered between meals, if tolerated. Intestinal iron absorption can be impaired in patients with CKD and may be further reduced by food and antacids. Among patients who are on daily dosing, giving one of the doses at bedtime may be a simple and effective expedient. Among patients who are on alternate-day dosing, administering iron on a set schedule (eg, Monday, Wednesday, and Friday) may improve adherence.</p><p>The daily dosing regimen is consistent with the KDIGO guidelines and our long-standing practice among patients with nondialysis CKD. The alternate-day dosing regimen is adopted from a shift in practice among the general population based upon small trials, which show that alternate-day dosing results in equivalent or better iron absorption and fewer side effects (see  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Dosing and administration (oral iron)'</a>). However, the alternate-day dosing regimen has not been tested in patients with CKD and, therefore, the efficacy of this regimen in this population is not known. Despite the lack of data, it is reasonable to choose the alternate-day regimen due to potential benefits with regards to iron absorption and side effects.</p><p>Among patients who do not achieve goals of iron supplementation (see <a class="local">'Goals of therapy'</a> above) after one to three months of adequately dosed oral iron therapy, we switch to intravenous iron. (See <a class="local">'Intravenous iron'</a> below.) </p><p>Other available iron preparations include <a class="drug drug_general" data-topicid="122021" href="/z/d/drug information/122021.html" rel="external">ferric maltol</a> [<a href="#rid27">27,28</a>], <a class="drug drug_general" data-topicid="96959" href="/z/d/drug information/96959.html" rel="external">ferric citrate</a> [<a href="#rid29">29</a>], and <a class="drug drug_general" data-topicid="91795" href="/z/d/drug information/91795.html" rel="external">sucroferric oxyhydroxide</a> [<a href="#rid30">30</a>]. Ferric citrate and sucroferric oxyhydroxide are oral phosphate binders that may be useful for oral iron supplementation in patients who also have hyperphosphatemia and in whom there is a desire to lower the serum phosphorous concentration [<a href="#rid31">31</a>]. However, we do not use them because they more expensive and do not offer greater efficacy or fewer side effects. (See  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Phosphate binders'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Intravenous iron</span><span class="headingEndMark"> — </span>There are a number of options available for treatment with an intravenous iron preparation including <a class="drug drug_general" data-topicid="9044" href="/z/d/drug information/9044.html" rel="external">ferumoxytol</a>, <a class="drug drug_general" data-topicid="9004" href="/z/d/drug information/9004.html" rel="external">iron sucrose</a>, <a class="drug drug_general" data-topicid="8936" href="/z/d/drug information/8936.html" rel="external">ferric gluconate</a> in sucrose complex, <a class="drug drug_general" data-topicid="90237" href="/z/d/drug information/90237.html" rel="external">ferric carboxymaltose</a>, and low-molecular-weight <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">iron dextran</a> [<a href="#rid31">31</a>]. When available, we prefer ferumoxytol because of fewer doses needed to replete iron stores. When ferumoxytol is not available, we give iron sucrose, although ferric gluconate is a reasonable alternative. We generally do not give iron dextran unless the other agents are unavailable. (See  <a class="medical medical_review" href="/z/d/html/1953.html" rel="external">"Treatment of iron deficiency in patients on dialysis"</a>.)</p><p>All of these products are equally effective in treating iron deficiency [<a href="#rid32">32</a>]. Major differences include cost, formulary/purchasing agreements, insurance coverage, and number of visits/time required to administer the full dose. The frequency of serious adverse events is comparable among products. One exception is high-molecular-weight <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">iron dextran</a>, which has a greater frequency of allergic reactions [<a href="#rid33">33,34</a>] and is no longer available in most of the world. A low-molecular-weight iron dextran preparation remains available but is used infrequently in patients with nondialysis CKD unless other preparations are not available. (See  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Allergic and infusion reactions'</a>.)</p><p>Dosing regimens for individual agents are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9044" href="/z/d/drug information/9044.html" rel="external">Ferumoxytol</a><strong> </strong>– The preferred regimen consists of two doses that are 510 mg administered at least a week apart. This regimen of two doses is usually sufficient to replete iron to therapeutic targets, although additional doses may be necessary for severe iron deficiency [<a href="#rid35">35-38</a>]. (See <a class="local">'Goals of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9004" href="/z/d/drug information/9004.html" rel="external">Iron sucrose</a><strong> </strong>– The preferred regimen consists of five doses of 200 mg administered over a two-week period. The 200 mg dose is generally well tolerated [<a href="#rid39">39</a>]. The regimen may be altered by administering higher doses less frequently, if necessary. As an example, 300 mg of iron sucrose can be administered once weekly, or less often, for a total dose of 600 to 900 mg [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8936" href="/z/d/drug information/8936.html" rel="external">Ferric gluconate</a><strong> in sucrose complex</strong> – The preferred regimen consists of three or four 250 mg doses, as needed, administered once weekly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="90237" href="/z/d/drug information/90237.html" rel="external">Ferric carboxymaltose</a><strong> </strong>– The preferred regimen consists of two doses of 750 mg, which may be administered in the same week [<a href="#rid41">41-43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="120585" href="/z/d/drug information/120585.html" rel="external">Ferric derisomaltose</a> <strong>(formerly known as</strong> <strong>iron isomaltoside) </strong>– The preferred dose is 20 mg/kg for a maximum dose of 1000 mg administered in a single intravenous infusion [<a href="#rid44">44-46</a>]. </p><p></p><p>Though it is not a preferred agent, low-molecular-weight <a class="drug drug_general" data-topicid="8574" href="/z/d/drug information/8574.html" rel="external">iron dextran</a> may be used if other agents are not available. A 25 mg test dose is generally administered first. If the test dose is tolerated, 500 to 1000 mg of iron dextran may be given in a single infusion; this dose can be repeated as required [<a href="#rid40">40,47-54</a>].</p><p>Caution must be exercised when administering intravenous iron. All intravenous iron preparations have been associated with anaphylaxis, although the incidence is not high (ie, less than 0.5 percent for non-dextran preparations) [<a href="#rid39">39</a>]. The most common side effects of intravenous iron are hypotension, nausea, vomiting, and abdominal discomfort; these effects are generally self limited. The management of such infusion reactions is discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Allergic and infusion reactions'</a>.)</p><p>More than other intravenous iron preparations, <a class="drug drug_general" data-topicid="90237" href="/z/d/drug information/90237.html" rel="external">ferric carboxymaltose</a> has been associated with a syndrome of high fibroblast growth factor 23 (FGF23), hypophosphatemia, phosphaturia, hypocalcemia, low vitamin D levels, and secondary hyperparathyroidism [<a href="#rid31">31,55-57</a>].</p><p class="headingAnchor" id="H399188131"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111938.html" rel="external">"Society guideline links: Anemia in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H13322193"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4418.html" rel="external">"Patient education: Dialysis or kidney transplantation — which is right for me? (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4414.html" rel="external">"Patient education: Hemodialysis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring iron stores</strong> – Iron deficiency is common among patients with chronic kidney disease (CKD). We monitor all patients with CKD for anemia and iron deficiency. Screening tests for iron deficiency include the percent transferrin saturation (TSAT), which is the plasma iron divided by total iron-binding capacity (TIBC) x 100, and the serum ferritin concentration. (See <a class="local">'Introduction'</a> above and <a class="local">'Continued monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for treatment</strong> – Indications for iron administration are based on the TSAT, ferritin, and, in some patients, the hemoglobin (Hb). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We give iron to most anemic patients with CKD who have a TSAT ≤20 percent and/or a serum ferritin concentration ≤100 ng/mL. Such patients are likely to have decreased iron stores (ie, have absolute iron deficiency). (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We give iron to some anemic patients with CKD who have a TSAT between 20 and 30 percent and ferritin between 100 and 500 ng/mL. Such patients may respond to supplemental iron administration with an increase in Hb level (or, among patients who are on an erythropoiesis-stimulating agent [ESA], with a reduction in ESA dose). (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do not treat with iron patients who have a TSAT &gt;30 percent, since such patients are unlikely to respond to iron. We do not routinely administer iron to patients with ferritin levels &gt;500 ng/mL and anemia, although each patient should be individually assessed. (See <a class="local">'Indications for treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral iron</strong> – Among most patients with nondialysis CKD who are selected for iron therapy, we give oral iron. We usually give <a class="drug drug_general" data-topicid="8444" href="/z/d/drug information/8444.html" rel="external">ferrous sulfate</a> 325 mg three times daily, which provides approximately 200 mg elemental iron. Although multiple other agents are available, they tend to be more expensive, without greater efficacy or consistently fewer side effects. (See <a class="local">'Route of administration'</a> above and <a class="local">'Oral iron'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous iron</strong> – We give intravenous iron to selected patients who are defined above. Multiple intravenous iron agents are available. Although regimens vary among individual agents, a course of intravenous iron usually provides 1000 mg elemental iron. (See <a class="local">'Route of administration'</a> above and <a class="local">'Intravenous iron'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610.</a></li><li><a class="nounderline abstract_t">Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10:1309.</a></li><li><a class="nounderline abstract_t">Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12:2465.</a></li><li><a class="nounderline abstract_t">Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000; 20:345.</a></li><li><a class="nounderline abstract_t">Batchelor EK, Kapitsinou P, Pergola PE, et al. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol 2020; 31:456.</a></li><li><a class="nounderline abstract_t">Farrington DK, Sang Y, Grams ME, et al. Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function. Am J Kidney Dis 2023; 81:201.</a></li><li class="breakAll">World Health Organization. Nutritional Anaemias: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization, 1968.</li><li><a class="nounderline abstract_t">Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50:1694.</a></li><li><a class="nounderline abstract_t">Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16:1416.</a></li><li><a class="nounderline abstract_t">Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7:2654.</a></li><li><a class="nounderline abstract_t">Kalantar-Zadeh K, Höffken B, Wünsch H, et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26:292.</a></li><li><a class="nounderline abstract_t">Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60:2406.</a></li><li><a class="nounderline abstract_t">Stancu S, Bârsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010; 5:409.</a></li><li><a class="nounderline abstract_t">Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005; 68:2846.</a></li><li><a class="nounderline abstract_t">Awan AA, Walther CP, Richardson PA, et al. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant 2021; 36:129.</a></li><li><a class="nounderline abstract_t">Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001; 16:967.</a></li><li><a class="nounderline abstract_t">Charytan C, Qunibi W, Bailie GR, Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005; 100:c55.</a></li><li><a class="nounderline abstract_t">Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006; 26:445.</a></li><li><a class="nounderline abstract_t">Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012; 1:CD007857.</a></li><li><a class="nounderline abstract_t">Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68:677.</a></li><li><a class="nounderline abstract_t">O'Lone EL, Hodson EM, Nistor I, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2019; 2:CD007857.</a></li><li><a class="nounderline abstract_t">Auerbach M, Adamson J, Bircher A, et al. On the safety of intravenous iron, evidence trumps conjecture. Haematologica 2015; 100:e214.</a></li><li><a class="nounderline abstract_t">Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015; 90:12.</a></li><li><a class="nounderline abstract_t">Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl (2011) 2012; 2:288.</a></li><li class="breakAll">https://www.nice.org.uk/guidance/ng8/resources/chronic-kidney-disease-managing-anaemia-51046844101 (Accessed on May 26, 2016).</li><li><a class="nounderline abstract_t">Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2:ii1.</a></li><li><a class="nounderline abstract_t">Pergola PE, Kopyt NP. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension. Am J Kidney Dis 2021; 78:846.</a></li><li><a class="nounderline abstract_t">Schmidt C, Allen S, Kopyt N, Pergola P. Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Womack R, Berru F, Panwar B, Gutiérrez OM. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial. Clin J Am Soc Nephrol 2020; 15:1251.</a></li><li><a class="nounderline abstract_t">Sanchez-Alvarez JE, Astudillo Cortes E, Seras Mozas M, et al. Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease. FOSFASTUR study. Nefrologia (Engl Ed) 2021; 41:45.</a></li><li><a class="nounderline abstract_t">Bazeley JW, Wish JB. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. Am J Kidney Dis 2022; 79:868.</a></li><li><a class="nounderline abstract_t">Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol 2016; 91:31.</a></li><li><a class="nounderline abstract_t">Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008; 19:833.</a></li><li><a class="nounderline abstract_t">Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010; 2010:338.</a></li><li><a class="nounderline abstract_t">Landry R, Jacobs PM, Davis R, et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005; 25:400.</a></li><li><a class="nounderline abstract_t">Spinowitz BS, Schwenk MH, Jacobs PM, et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005; 68:1801.</a></li><li><a class="nounderline abstract_t">Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19:1599.</a></li><li><a class="nounderline abstract_t">Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:386.</a></li><li><a class="nounderline abstract_t">Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005; 46:283.</a></li><li><a class="nounderline abstract_t">Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38:988.</a></li><li><a class="nounderline abstract_t">Grimmelt AC, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009; 71:125.</a></li><li><a class="nounderline abstract_t">Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant 2014; 29:833.</a></li><li><a class="nounderline abstract_t">Roger SD, Gaillard CA, Bock AH, et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrol Dial Transplant 2017; 32:1530.</a></li><li><a class="nounderline abstract_t">Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2016; 31:646.</a></li><li><a class="nounderline abstract_t">Bhandari S, Allgar V, Lamplugh A, et al. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol 2021; 22:115.</a></li><li><a class="nounderline abstract_t">Kalra PA, Bhandari S, Spyridon M, et al. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol 2020; 21:539.</a></li><li><a class="nounderline abstract_t">Jain AK, Bastani B. Safety profile of a high dose ferric gluconate in patients with severe chronic renal insufficiency. J Nephrol 2002; 15:681.</a></li><li><a class="nounderline abstract_t">Sloand JA, Shelly MA, Erenstone AL, et al. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies. Perit Dial Int 1998; 18:522.</a></li><li><a class="nounderline abstract_t">Prakash S, Walele A, Dimkovic N, et al. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 2001; 21:290.</a></li><li><a class="nounderline abstract_t">Blaustein DA, Schwenk MH, Chattopadhyay J, et al. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int Suppl 2003; :S72.</a></li><li><a class="nounderline abstract_t">Bastani B, Jain A, Pandurangan G. Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure. Nephrology (Carlton) 2003; 8:8.</a></li><li><a class="nounderline abstract_t">Danda RS, Kirk LJ, Pergola PE. High-dose iron gluconate in chronic kidney disease patients. Nephrology (Carlton) 2004; 9:47.</a></li><li><a class="nounderline abstract_t">Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt; or =250 mg) administration. Am J Kidney Dis 2003; 41:651.</a></li><li><a class="nounderline abstract_t">Kosch M, Bahner U, Bettger H, et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001; 16:1239.</a></li><li><a class="nounderline abstract_t">Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol 2020; 16:7.</a></li><li><a class="nounderline abstract_t">Wolf M, Rubin J, Achebe M, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA 2020; 323:432.</a></li><li><a class="nounderline abstract_t">Schaefer B, Zoller H, Wolf M. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. J Clin Endocrinol Metab 2022; 107:1009.</a></li></ol></div><div id="topicVersionRevision">Topic 1943 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073612" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hematocrit level and associated mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10361870" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hematocrit levels and hospitalization risks in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675424" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928336" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of hematocrit on morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32041774" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36181996" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36181996" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8914038" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A randomized controlled study of iron supplementation in patients treated with erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11427634" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989744" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The evaluation of iron status in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645533" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737617" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A randomized trial of iron deficiency testing strategies in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019121" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316362" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31641775" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11328902" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824508" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035697" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A randomized controlled trial of oral versus intravenous iron in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258974" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Parenteral versus oral iron therapy for adults and children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27321965" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30790278" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Parenteral versus oral iron therapy for adults and children with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25944640" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : On the safety of intravenous iron, evidence trumps conjecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25572192" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The safety of intravenous iron preparations: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018948" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chapter 1: Diagnosis and evaluation of anemia in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018948" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chapter 1: Diagnosis and evaluation of anemia in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206425" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34029682" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34640466" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32694162" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33239181" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease. FOSFASTUR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34758368" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26408108" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : How we diagnose and treat iron deficiency anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18369084" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-molecular weight iron dextran: a wolf in sheep's clothing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239816" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical use of intravenous iron: administration, efficacy, and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16088081" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16164657" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525001" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ferumoxytol for treating iron deficiency anemia in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19176796" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16112047" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684551" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intravenous iron sucrose: establishing a safe dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203504" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23963731" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28339831" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26250435" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33784968" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33302891" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12495284" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety profile of a high dose ferric gluconate in patients with severe chronic renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848632" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11475345" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531777" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15012743" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996310" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High-dose iron gluconate in chronic kidney disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612989" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt;or =250 mg) administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11390726" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31519999" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016310" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850000" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
